VIDEO: Effective therapies needed for uveal melanoma

NEW YORK — Some clinical trials evaluating standard melanoma immunotherapies have been disappointing for metastatic uveal melanoma, Alexander Shoushtari, MD, assistant attending physician at Memorial Sloan Kettering Cancer Center, said at HemOnc Today Melanoma and Cutaneous Malignancies.In his presentation at the meeting, Shoushtari discussed recent trials for uveal melanoma that have targeted proteins like MEK and kinase C, and he also discussed the future landscape of targeted treatments.